BIOTECH & PHARMA

    Biotech and pharma stocks listed on the ASX.

    Zelira Therapeutics medical cannabis trial treat insomnia ASX ZLD phase 1b 2a

    Zelira Therapeutics reveals more positive results from medical cannabis trial to treat insomnia

    PolyNovo NovoSorb Biodegradable Temporizing Matrix BTM burn ASX PNV

    PolyNovo posts record US quarterly sales, secures debt facility for Melbourne factory expansion

    Mesoblast acute respiratory distress syndrome ARDS COVID-19 ASX MSB FDA

    Mesoblast’s remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress

    Rhythm Biosciences ColoSTAT biomarker colorectal cancer antibodies ASX RHY

    Rhythm Biosciences reports positive results for lead biomarker in blood test for colorectal cancer screening

    Bionomics generalised anxiety disorder patients Phase 2a data BNC210 ASX BNO

    Bionomics publishes BNC210 anti-anxiety trial data in Biological Psychiatry, prepares for next study

    Noxopharm ASX NOX idronoxil COVID-19

    Noxopharm’s idronoxil could potentially prevent COVID-19 fatalities, clinical trials to begin

    OncoSil Medical breakthrough device treatment pancreatic cancer CE Marking approval ASX OSL

    OncoSil Medical obtains CE Mark and breakthrough device designation for its pancreatic tumour isotope

    AusCann ASX AC8 hard shell capsule clinical trial cannabis CBD TGA

    AusCann to begin distributing THC-CBD medicinal cannabis capsules throughout Australia

    Genetic Signatures coronavirus test kit diagnostic UK EU Europe United Kingdom ASX GSS

    Genetic Signatures applies to market coronavirus test kit throughout UK and EU

    Althea Group record revenues medicinal cannabis sales ASX AGH patients

    Althea Group bags record revenues as medicinal cannabis sales continue growing worldwide

    Cellmid rapid diagnostic test COVID-19 coronavirus CDY ASX

    Cellmid set to commercialise 15 minute diagnostic test for COVID-19

    MedAdvisor app medicine delivery service ASX MDR COVID-19

    MedAdvisor launches home delivery service for pharmacy meds

    Impression Healthcare FDA cannabinoid drug candidate IHL-42X Camargo Pharmaceuticals ASX IHL

    Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X

    Amplia Therapeutics ASX ATX FDA Amplia orphan drug designation pancreatic cancer

    Amplia Therapeutics receives FDA orphan drug designation for pancreatic cancer

    Paradigm Biopharmaceuticals ASX PAR Zilosul COVID-19 knee osteoarthritis

    Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact

    Atomo Diagnostics IPO ASX medical diagnostic testing HIV RDT

    Atomo Diagnostics launches $30m IPO to target global rapid diagnostic testing market

    Impression Healthcare CBD inhalers Australia Special Access Scheme lung inflammation COVID-19 coronavirus Asthma COPD Ventilin

    Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme

    Multiple Sclerosis NeuroScientific Biopharmaceuticals ASX NSB EmtinB

    NeuroScientific’s EmtinB drug achieves positive results in pre-clinical MS research

    OncoSil unresectable pancreatic cancer treatment FDA ASX OSL breakthrough device designation

    FDA grants breakthrough device designation for OncoSil

    Nyrada brain injury cholesterol lowering studies COVID-19 coronavirus ASX NYR

    Nyrada advances brain injury and cholesterol lowering studies, remains unaffected by COVID-19

    Respiri coronavirus COVID19 China Wheezo ASX RSH

    Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China

    Load more
    Small Caps ASX Australian stock market
    Small Caps is Australia's #1 site for news & information on ASX listed small cap companies.

    Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
    Copyright 2020 Small Caps. All rights reserved.